Patients of all ages tended to benefit from switching treatments, but there was a weak decreasing effect of DORA therapy with age, which could suggest that the orexin system might play less of a role in geriatric insomnia patients compared with younger individuals. This evidence concerns the gene HCRT and insomnia measurement.